Pfizer Inc. (PFE) saw its shares decline 2.7% to $25.21 on Thursday, capping a week of losses following the announcement that Chief Financial Officer Dave Denton will step down in August. The departure has stirred investor unease about the company's leadership succession, execution strategy, and competitive positioning in the obesity drug market, even as Pfizer reaffirmed its full-year 2026 financial forecast.
Denton, a key figure in articulating Pfizer's post-COVID strategy to Wall Street, will leave on August 15. Cecile Guegan will serve as interim CFO starting the next day while the company conducts an internal and external search for a permanent replacement. CEO Albert Bourla praised Denton as a “steady and trusted steward,” and Denton expressed confidence that Pfizer is “in excellent hands.”
The stock's decline outpaced broader market gains on Thursday; the S&P 500 rose 1.08% and the Dow Jones Industrial Average gained 0.14%. Pfizer also lagged behind peers Johnson & Johnson, Eli Lilly, and Abbott Laboratories. Trading volume surged well above the 50-day average, indicating the move was more than typical pre-holiday positioning.
Over the four-session week, Pfizer shares dropped 3.8%, sliding from a June 12 close of $26.21. The pullback occurred even as chip stocks and easing geopolitical tensions lifted the Nasdaq and S&P 500 to new highs.
Pfizer attempted to calm markets in a June 18 regulatory filing, reaffirming its 2026 guidance: revenue between $59.5 billion and $62.5 billion, and adjusted diluted earnings per share in the range of $2.80 to $3.00. However, Scotiabank analyst Louise Chen noted that Denton's exit has left investors questioning the reliability of that outlook, the timeline for a successor, and the company's readiness to enter the obesity drug market.
The obesity drug race remains dominated by Eli Lilly and Novo Nordisk, while Pfizer is striving to catch up. The company acquired Metsera, an obesity drug developer, after a competitive bidding process. CEO Bourla declared in January that Pfizer is “all in on obesity,” and the company has lined up 10 Phase 3 studies on Metsera's obesity drugs this year.
Yet the landscape is shifting. Drug pricing pressures have intensified, and some market forecasts have been revised downward. Jefferies analyst Michael Leuchten earlier this year noted that the projected $150 billion market opportunity for obesity drugs has diminished. Still, some analysts believe that lower prices could expand the patient base and sustain demand.
As markets reopen on Monday after the Juneteenth holiday, investors will be watching for any updates on the CFO search and for signs of whether the selling pressure will continue. The company cautioned in its filing that actual results could deviate from forecasts due to research outcomes, regulatory actions, competitive dynamics, pricing pressures, COVID-related demand shifts, tariffs, and deal execution risks. If the CFO change amplifies concerns about spending discipline or integration of acquisitions, shares may remain under pressure despite the reaffirmed outlook.
